News

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Submitting this IND is the most important milestone the Company has met thus far in the clinical development of our

These neutralizing effects were found to be comparable to or better than those seen with antibody candidates derived from patients who had recovered from COVID-19. The data were

Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant

SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.1,2 The approval by the European Commission was

JTX-1811, which is a monoclonal antibody, is said to have been designed by Jounce Therapeutics to preferentially deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. The immunotherapy candidate’s target

AML is one of the most common acute leukemias in adults. The approval is based on results from the pivotal Phase 3 QUAZAR® AML-001 study in which treatment

The company has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application of brequinar to treat Covid-19. Brequinar is an

OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. FDA’s clearance of the IND

VIR-7831 is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that is being developed for the early treatment of the viral disease in patients who